Biogen says it will up Samsung Bioepis cut
Biogen has confirmed plans to purchase a 49.9% equity stake in the Samsung Bioepis biosimilars joint venture between itself and Samsung BioLogics, praising the “attractive, value-creation opportunity”.
You may also be interested in...
Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.
Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.
Teva has wrapped up an earlier deal with Sanofi that will see the French giant take command of its novel TL1A inhibitor currently in a Phase IIb study for ulcerative colitis and Crohn’s disease.